Last reviewed · How we verify
ONO-9054
At a glance
| Generic name | ONO-9054 |
|---|---|
| Sponsor | Ono Pharma USA Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG) (PHASE2)
- Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma (PHASE1)
- Single Dose Escalation Study of ONO-9054 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-9054 CI brief — competitive landscape report
- ONO-9054 updates RSS · CI watch RSS
- Ono Pharma USA Inc portfolio CI